Confirmation that heparin is an alternative means of promoting early reperfusion

被引:8
作者
Braga, JC
Esteves, FP
Esteves, JP
Latado, AL
Godinho, AG
Azevedo, A
Brito, JC
Silva, PR
Teixeira, MS
Souza, VP
Rabelo, A
Rocha, MS
机构
[1] Hosp Portugues, Coronary Care Unit, BR-40146900 Salvador, BA, Brazil
[2] Fundacao Bahiana Cardiol, BR-40146900 Salvador, BA, Brazil
关键词
heparin; primary angioplasty; coronary patency;
D O I
10.1097/00019501-199809060-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background New strategies to increase coronary patency rate before primary angioplasty are under discussion. We tested the hypothesis that use of a high dose of a standard heparin bolus could achieve an acceptable rate of re-opening occluded infarct-related arteries thus providing an alternative to chemical thrombolysis before admission of the patient to hospital, and a pretreatment for primary angioplasty. Methods Forty-eight patients who presented within 12 h of acute myocardial infarction with ST segment elevation were assigned randomly to groups to receive aspirin (200 mg orally) and high-dose standard heparin 300 U/kg as an intravenous bolus (n = 25), or aspirin and placebo bolus (n = 23), Thereafter, all patients underwent coronary arteriography to assess their suitability for primary angioplasty. Results The high-dose heparin group had greater patency rate (Thrombolysis in Myocardial Infarction grade 2 or 3 flow in the infarct-related artery) than the placebo group (52% compared with 13%, P = 0.006). Hemorrhages related to the puncture site that required blood transfusion occurred in two of 25 and in one of 23 patients in the high-dose heparin and placebo groups, respectively. Conclusion Our study suggests that high-dose standard heparin does have a thrombolytic action when administered as an intravenous bolus. Coronary Artery Dis 9:335-338 (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:335 / 338
页数:4
相关论文
共 19 条
  • [1] AGNELLI G, 1988, THROMB HAEMOSTASIS, V60, P311
  • [2] PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR
    BAJZAR, L
    MANUEL, R
    NESHEIM, ME
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) : 14477 - 14484
  • [3] Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
    Bajzar, L
    Nesheim, M
    Morser, J
    Tracy, PB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) : 2792 - 2798
  • [4] BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576
  • [5] BLEICH SD, 1993, Z KARDIOL, V82, P179
  • [6] BUSZMAN P, 1995, J AM COLL CARDIOL S, V25, pA310
  • [7] EVIDENCE FAVORING USE OF ANTICOAGULANTS IN HOSPITAL PHASE OF ACUTE MYOCARDIAL-INFARCTION
    CHALMERS, TC
    MATTA, RJ
    SMITH, H
    KUNZLER, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (20) : 1091 - 1096
  • [8] DARWICH RN, 1996, ARQ BRAS CARDIOL S1, V67, P128
  • [9] PREVALENCE OF TOTAL CORONARY-OCCLUSION DURING THE EARLY HOURS OF TRANSMURAL MYOCARDIAL-INFARCTION
    DEWOOD, MA
    SPORES, J
    NOTSKE, R
    MOUSER, LT
    BURROUGHS, R
    GOLDEN, MS
    LANG, HT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (16) : 897 - 902
  • [10] HEMORRHAGIC DOSES OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS INDUCE A PLATELET DEFECT
    FERNANDEZ, F
    NGUYEN, P
    VANRYN, J
    OFOSU, FA
    HIRSH, J
    BUCHANAN, MR
    [J]. THROMBOSIS RESEARCH, 1986, 43 (04) : 491 - 495